Methylenetetrahydrofolate reductase C677T mutation, plasma homocysteine, and folate in subjects from northern Italy with or without angiographically documented severe coronary atherosclerotic disease: evidence for an important genetic-environmental interaction.

Moderate elevation of plasma total homocysteine (tHcy) is a strong and independent risk factor for coronary artery disease (CAD). It can result from genetic or nutrient-related disturbances in the transsulfuration or remethylation pathways for Hcy metabolism. A point mutation (C677T; Ala-to-Val) in the gene encoding the 5,10-methylenetetrahydrofolate reductase (MTHFR) has been recently reported to render the enzyme thermolabile and less active. Studies on the role of this mutation as a risk factor for CAD have given conflicting results. We studied a total of 415 subjects, 278 with angiographically documented multivessel CAD and 137 with angiographically documented normal coronary arteries. The overall frequency of the MTHFR V/V homozygous genotype was 15.7% (with 52.5% heterozygous and 31.8% normal). Subgroup analysis showed no significant differences between CAD and CAD-free subjects. A genotype/phenotype correlation study showed a marked effect of folate on the association between MTHFR genotypes and tHcy. Among individuals with folate levels below the median (11.5 nmol/L), fasting tHcy was significantly increased not only in V/V homozygotes (by 59%) but also, at intermediate values, in A/V heterozygotes (by 21% on average). Conversely, the mutation resulted neutral with respect to tHcy levels in subjects with adequate folate levels. We conclude that, in our population, the MTHFR C677T mutation is rather common, but it does not appear to be associated per se to CAD. A genetic-environmental interaction may contribute to the vascular risk by elevating tHcy when folate status is low.

[1]  G. Hankey,et al.  Homocysteine and vascular disease , 1999, The Lancet.

[2]  S. Vollset,et al.  Plasma homocysteine levels and mortality in patients with coronary artery disease. , 1997, The New England journal of medicine.

[3]  E. Sacchi,et al.  High Frequency of the C677T Mutation in the Methylenetetrahydrofolate Reductase (MTHFR) Gene in Northern Italy , 1997, Thrombosis and Haemostasis.

[4]  T. Raghunathan,et al.  Myocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methylenetetrahydrofolate reductase gene. , 1997, Circulation.

[5]  H. Blom,et al.  The 677C-->T mutation in the methylenetetrahydrofolate reductase gene: associations with plasma total homocysteine levels and risk of coronary atherosclerotic disease. , 1997, Atherosclerosis.

[6]  G. Boers.  Hyperhomocysteinemia as a Risk Factor for Arterial and Venous Disease. A Review of Evidence and Relevance , 1997, Thrombosis and Haemostasis.

[7]  R. Rozen.  Genetic Predisposition to Hyperhomocysteinemia: Deficiency of Methylenetetrahydrofolate Reductase (MTHFR) , 1997, Thrombosis and Haemostasis.

[8]  J. Witteman,et al.  Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. , 1997, JAMA.

[9]  F. Nieto,et al.  The effects of folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotypes. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[10]  S. Daly,et al.  Thermolabile variant of 5, 10-methylenetetrahydrofolate reductaseassociated with low red-cell folates: implications for folate intake recommendations , 1997, The Lancet.

[11]  Y. Yazaki,et al.  Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. , 1997, Circulation.

[12]  P. Frosst,et al.  Correlation of a common mutation in the methylenetetrahydrofolate reductase gene with plasma homocysteine in patients with premature coronary artery disease. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[13]  S. Vasikaran,et al.  Methylenetetrahydrofolate reductase gene and coronary artery disease. , 1997, Circulation.

[14]  A. Marian,et al.  A common mutation in methylenetetrahydrofolate reductase gene is not a major risk of coronary artery disease or myocardial infarction. , 1997, Atherosclerosis.

[15]  W. Willett,et al.  Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. , 1996, Circulation.

[16]  S. Vollset,et al.  Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (> or = 40 micromol/liter). The Hordaland Homocysteine Study. , 1996, The Journal of clinical investigation.

[17]  A. Evans,et al.  Homocysteine and risk of premature coronary heart disease. Evidence for a common gene mutation. , 1996, Circulation.

[18]  J. Buring,et al.  Genetic polymorphism of methylenetetrahydrofolate reductase and myocardial infarction. A case-control study. , 1996, Circulation.

[19]  A. Paterson,et al.  Evidence for genetic anticipation in non-Mendelian diseases. , 1996, American journal of human genetics.

[20]  D. Wilcken,et al.  Distribution in healthy and coronary populations of the methylenetetrahydrofolate reductase (MTHFR) C677T mutation. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[21]  N. Samani,et al.  Genetic analysis of thermolabile methylenetetrahydrofolate reductase as a risk factor for myocardial infarction. , 1996, QJM : monthly journal of the Association of Physicians.

[22]  R. Rozen.  Molecular genetic aspects of hyperhomocysteinemia and its relation to folic acid. , 1996, Clinical and investigative medicine. Medecine clinique et experimentale.

[23]  G. Oakley,et al.  More folic acid for everyone, now. , 1996, The Journal of nutrition.

[24]  R. Paroni,et al.  Prevalence of Moderate Hyperhomocysteinemia in Patients with Early-Onset Venous and Arterial Occlusive Disease , 1995, Annals of Internal Medicine.

[25]  M. den Heyer,et al.  Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida , 1995, The Lancet.

[26]  G. Omenn,et al.  A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. , 1995, JAMA.

[27]  J. Witte,et al.  Genetic dissection of complex traits. , 1994, Nature genetics.

[28]  J. Selhub,et al.  Vitamin B-6 deficiency vs folate deficiency: comparison of responses to methionine loading in rats. , 1994, The American journal of clinical nutrition.

[29]  P. Wong,et al.  Thermolabile Defect of Methylenetetrahydrofolate Reductase in Coronary Artery Disease , 1993, Circulation.

[30]  H. Sauberlich,et al.  Plasma Folate Adequacy as Determined by Homocysteine Level a , 1992, Annals of the New York Academy of Sciences.

[31]  M. Norusis,et al.  Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. , 1991, American journal of human genetics.

[32]  S. S. Kang,et al.  Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. , 1988, American journal of human genetics.

[33]  D. Wilcken,et al.  The pathogenesis of coronary artery disease. A possible role for methionine metabolism. , 1976, The Journal of clinical investigation.

[34]  K. Mccully.  Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. , 1969, The American journal of pathology.

[35]  J. Selhub,et al.  Homocysteine and thrombotic disease. , 1997, Blood.

[36]  P. Frosst,et al.  Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. , 1996, American journal of human genetics.

[37]  I. Rosenberg,et al.  Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. , 1996, Circulation.

[38]  A. Motulsky.  Nutritional ecogenetics: homocysteine-related arteriosclerotic vascular disease, neural tube defects, and folic acid. , 1996, American journal of human genetics.

[39]  R. Matthews,et al.  A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase , 1995, Nature Genetics.

[40]  Y. Sako,et al.  Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. , 1987, Journal of chromatography.